Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 4Thoracic 2Other hematologic neoplasm 2Gastrointestinal 2Sarcoma 1Plasma cell 1Lymphoid 1CNS 1

Conditions

Leukemia, Myeloid, Acute 2

Interventions

Cytarabine 905Cyclophosphamide 899fludarabine 525venetoclax 489fludarabine phosphate 468Azacitidine 460Rituximab 431Methotrexate 419Etoposide 320Filgrastim 299Busulfan 296Dexamethasone 286Vincristine 285Daunorubicin 283Peripheral Blood Stem Cell Transplantation 258Whole-Body Irradiation 243Mycophenolic Acid 232Decitabine 230Granulocyte Colony-Stimulating Factor 227Tacrolimus 220Imatinib Mesylate 211Idarubicin 205Melphalan 202Cyclosporine 182Doxorubicin 177Radiotherapy 169Prednisone 163Dasatinib 163Mitoxantrone 161Lenalidomide 160

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
ficlatuzumab × Other hematologic neoplasm × Clear all
NCT04100330 2020-03-31

CyFi2

AVEO Pharmaceuticals, Inc.

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02109627 2020-03-24

Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML

University of California, San Francisco

Phase 1 Terminated
17 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡